Massive Bio vs Mendel (2026)
One of these sells enrolments and the other sells the capability underneath them, which is the distinction to settle before comparing anything else. Massive Bio is an oncology matching and enrolment platform: it extracts structured information from records, matches against a very large active trial list, has certified case managers audit every match, and has peer reviewed prospective evidence for the product itself. Mendel is a chart abstraction platform whose reasoning serves prescreening, cohort building and observational research alike, with a specific architecture combining language models and symbolic reasoning precisely because generation alone produces confident errors, and it can run inside your own environment. If the mandate is enrol more oncology patients this year, Massive Bio is pointed at exactly that. If it is stop paying clinicians to read charts, Mendel is the broader purchase.
- Human oversight is structural rather than asserted, with certified oncology case managers auditing every generated match before it is acted on.
- Peer reviewed prospective evidence exists for the matching product itself, which is rare in this category and rarer still for a company of this size.
- It reaches patients directly as well as through sites, so a patient whose oncologist has no trial programme is not excluded by their institution's capability.
- Chart abstraction is the underlying capability rather than matching alone, so the same platform serves cohort building, observational studies and prescreening rather than one workflow.
- The architecture is specific and defensible: language models paired with symbolic reasoning over a clinical hypergraph, chosen because generation alone produces confident abstraction errors.
- It can be hosted inside the customer's own environment, which is the strongest residency position among the trial vendors here and often the deciding factor for an academic centre.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Massive Bio and Mendel are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Massive Bio | Mendel |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | 2015 | 2016 |
| Headquarters | Boca Raton, Florida | San Jose, California, United States |
| Website | massivebio.com | mendel.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Massive Bio its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Mendel, Massive Bio grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Mendel its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Massive Bio, Mendel grades higher on several axes, including Model and Technology Transparency, AI Governance and Bias Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Massive Bio or Mendel?
On the axes where the AI Health Index separates them, Massive Bio grades higher on several axes, including Model Supply Chain Disclosure, Clinical and Operational Evidence and HIPAA and BAA Posture, and Mendel grades higher on several axes, including Model and Technology Transparency, AI Governance and Bias Disclosure and AI Liability and Recourse. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Massive Bio and Mendel differ most?
The widest separation the AI Health Index records between Massive Bio and Mendel is on Deployment Model and Data Residency, where Massive Bio grades C and Mendel grades A. That axis sits in the Integration and Deployment group, so it should carry the most weight for a buyer whose binding constraint is how the product lands in the stack already in place.
Where do Massive Bio and Mendel grade the same?
The AI Health Index grades Massive Bio and Mendel the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These products are adjacent rather than identical: one is a matching and enrolment service for oncology, the other is a chart abstraction platform of which prescreening is one application, so a buyer comparing them should establish whether they are buying enrolment outcomes or a reusable abstraction capability. Neither vendor publishes a security attestation or trust centre and neither publishes pricing. Neither publishes a false negative rate for eligibility screening, which is the number that matters most, since an eligible patient never surfaced is invisible to every metric either vendor reports.